Sangoma Posts $50.1M Q1 Revenue, $6.9M Free Cash Flow Ahead of BRC Takeover
SANG sits 31% above its 52-week low of $3.4 on light trading volume (0.4× avg).
Summary
Sangoma reported Q1 fiscal 2027 revenue of $50.1M (flat year over year), a $2.9M net loss and $6.9M of free cash flow, and suspended guidance while its $204M sale to BRC Group Holdings works toward a December 2026 shareholder vote and January 2027 close.
Key Events · Earnings and Guidance · SANG
-
Q1 Revenue Flat at $50.1M
Revenue was $50,062K versus $50,332K a year earlier, a 1% decline, but 0.49% above the $49,816K posted in Q4 fiscal 2026. Service revenue of $45,541K was 91% of the total.
-
Free Cash Flow Doubles to $6.9M
Net cash from operations was $8,771K, or 120% of Adjusted EBITDA, and free cash flow was $6,930K ($0.21 per share) versus $3,230K ($0.10) a year earlier. Total debt fell to $22,150K from $42,750K after $5,150K of term-loan repayments.
-
Net Loss Widens, EBITDA Slips
Net loss was $2,885K ($0.09 per share) versus $2,647K ($0.08), and Adjusted EBITDA fell 8% to $7,309K, or 15% of revenue, from $7,987K and 16%.
-
Guidance Suspended for BRC Deal
Sangoma will not hold an earnings call and is suspending fiscal 2027 guidance because of the pending acquisition by BRC Group Holdings at $4.925 cash plus 0.04767 BRC shares per share.
Analysis · SANG · Technology
These are the first quarterly results since Sangoma agreed to be bought by BRC Group Holdings, and they show a business holding steady rather than deteriorating: revenue of $50.1M was essentially flat year over year and up 0.49% sequentially, gross margin held at 70%, and free cash flow more than doubled to $6.9M. That matters because the $4.925 cash plus 0.04767 BRC shares per share deal still needs a shareholder vote in December 2026 and court and regulatory approvals before a January 2027 close — a stable operating picture removes a reason for holders to second-guess the consideration. On the negative side, net loss widened to $2.9M and Adjusted EBITDA fell 8% to $7.3M, while an unremediated internal-control material weakness carried over from the fiscal 2026 MD&A. Management also suspended fiscal 2027 guidance and skipped the earnings call because of the pending transaction, so the deal timetable is now the only thing that moves the stock.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SANG was trading at $4.47 on NASDAQ in the Technology sector, with a market capitalization of approximately $149.8M. The 52-week trading range was $3.40 to $5.42. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.